TCTR20180905005尚未招募1 期
A Bioequivalence study of a randomized,open-label,single-dose,two-way crossover design with two-period,two-treatment and two-sequence of Quetiapine200mg immediate release tablets imported by Great Eastern Drug Co.,Ltd.(hereinafter referred to as“Re
Bio-innova and Synchron.Co.,Ltd0 个研究点目标入组 36 人开始时间: 2018年9月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Willingness to provide written informed consent prior to participate in the study.
- •2.Healthy Thai subjects are between 18 to 55 years of age.
- •3.The Body Mass Index (BMI) ranges from 18 to 25 kg/m2.
- •4.Comprehensive of the nature and purpose of the study and compliance with the requirement of the entire protocol and allow investigators to draw 10 mL of blood for monitoring subjects’ safety after the completion of the study.
- •5.Negative urine pregnancy test for women and no breast-feeding.
- •6.Absence of significant diseases or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or surgery during the screening. Some of the laboratory values e.g. Complete blood count etc. that out of the normal range will be carefully considered by physician.
排除标准
- •1.History or evidence of allergy or hypersensitivity to Quetiapine or any related drugs or any of the excipients of this product.
- •2.Subject with B.P. is Systolic B.P < 90, ≥140 mm/Hg, Diastolic B.P < 60, ≥90 mm/Hg or pulse rate > 100 beats per minute.
- •3.Serum bilirubin greater than 1.5 times the upper limit of reference range (ULRR).*
- •4.Serum creatinine greater than 1.5 times the upper limit of reference range (ULRR). *
- •5.Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2 times the upper limit of reference range (ULRR).*
- •6.Positive of hepatitis B or C virus or HIV.
- •7.12-lead ECG demonstrating QTc >400 msec, a QRSD >120 msec or with an abnormality considered clinically significant at Screening. If QTc exceeds 400 msec, or QRSD exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc or QRSD values should be used to determine the subject’s eligibility*.
- •8.Subject had clinically abnormal Chest X-ray*
- •9.History or evidence of heart, renal, hepatic disease, pulmonary obstructive disease, bronchial asthma, hypertension, thyroid disease or glaucoma.
- •10.History or evidence of gastrointestinal disorder likely to influence drug absorption or previous GI surgery other than appendectomy.
- •11.Any major illness in the past 3 months or any significant ongoing chronic medical illness.
- •12.History of psychiatric disorder or depression.
- •13.History of epilepsy, seizure or increase risk of seizure (e.g. severe head trauma)
- •14.History of suicidal thoughts, behavior or suicide attempt.
- •15.History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
- •16.History of usually smoking (more than 10 cigarettes per day), if moderate smokers (less than 10 cigarettes per day) cannot stop at least 7 days before the study drug administration and until the completion of the study.
- •17.High caffeine consumption (more than 5 cups of coffee or tea per day) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
- •18.Grapefruit or its products consumption and cannot stop at least 7 days before the study drug administration and until the completion of the study.
- •19.Positive drug abused test in urine (Marijuana (THC), Cocaine, Opioids, Amphetamine and Benzodiazepines).
- •20.Receipt of any prescription drug therapy within 14 days or 5 half-lives (whichever longer) preceding the first dose of study medication or over-the-counter (OTC) drugs or herbal medicines/food supplement within 7 days or hormonal methods of contraception within 28 days (Depo-Provera® must be discontinued at least 6 months) prior to receiving the first dose of study medication.
- •21.History of difficulty in accessibility of veins in left and right arm.
- •22.Blood donation (one unit or 450 mL) within the past 3 months before the study.
- •23.Participation in any clinical study within the past 3 months before the study.
- •24.Subjects who are unwilling or unable to comply with the lifestyle guidelines described in this protocol.
- •(* Depend on decision of principal invest
研究者
相似试验
尚未招募
1 期
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Olmesartan medoxomil 40 mg tablets relative to Olmetec® in healthy Thai volunteers under fasting condition (A Pilot Study)Bioequivalence study in healthy volunteersBioequivalenceOlmesartanTCTR20180328003Bio-innova and Synchron.Co.,Ltd8
尚未招募
1 期
A Bioequivalence study of a randomized, open-label, single-dose, two-way crossover design with two-period, two-treatment and two-sequence of Dutasteride 0.5 mg soft capsules relative to Avodart® in healthy Thai male volunteers under fasting conditioBioequivalence study in healthy thai male volunteersBioequivalenceDutasterideTCTR20180902002Bio-innova and Synchron.Co.,Ltd28
尚未招募
1 期
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Pitavastatin Calcium Tablet 2 mg relative to Livalo(R) Tablet 2 mg (Pitavastatin Calcium) in healthy Thai volunteers under fasting conditioBioequivalence studyPitavastatinTCTR20200306002Bio-innova and Synchron.Co.,Ltd28
尚未招募
1 期
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Pitavastatin Calcium Tablet (2 mg) relative to Originator Pitavastatin Calcium Tablet (2 mg) in healthy Thai volunteers under fasting condition.Bioequivalence study in healthy volunteersBioequivalence,PitavastatinTCTR20170105001Bio-innova and Synchron.Co.,Ltd44
尚未招募
1 期
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Apixaban Film-coated tablets (5 mg) relative to Originator Apixaban Film-coated tablets (5 mg) in healthy Thai volunteers under fasting conditioBioequivalence study in healthy volunteersBioequivalenceApixabanTCTR20180308002Bio-innova and Synchron.Co.,Ltd30